Neuro News Roundup: Hot Topics and Key Insights From Women in Medicine
In celebration of Women’s Physician Day, held February 3, 2022, take a look back at some of the latest conversations and news that were driven and delivered by women in neurology.
In recent months, the NeurologyLive® team has been covering the news and conducting interviews with a variety of expert women physicians on the latest updates in the clinical care of individuals with different neurological conditions such as multiple sclerosis, migraine, epilepsy, Alzheimer disease, and many more.
For National Women Physicians Day—celebrated annually on February 3—the team has culminated some of the key clinical insights, data presentations, and hot topics in neurology that we have discussed with and that included leading women in medicine. These select items only scratch the surface of the full scale of women's contributions to the field, and NeurologyLive®'s conversations with them.
Click here for more coverage of the
EXPERT INSIGHTS
LATEST LITERATURE
International Panel of Experts Proposes New Diagnostic Criteria for MOG Antibody Associated Disease
"Tools that quantify visual impairment would be valuable in MOGAD, given the predilection for the optic nerve," Banwell et al wrote. "The opticospinal impairment scale might prove useful in this regard. Prospective longitudinal OCT studies might further inform our understanding of the effect of MOGAD on the optic pathway and differences between MOGAD, multiple sclerosis, and AQP4-IgG-seropositive NMOSD."
Antiseizure Agent EQU-001 Shows Safety, Tolerability, and Preliminary Efficacy in Phase 2 Study
"Patients living with epilepsy face the debilitating impact of focal seizures, as well as the debilitating side effects of many available medications,” French said in a statement.5 "There is a great need for new and efficacious medications that are well tolerated by patients with fewer AEs. If in fact EQU-001 is working through a novel anti-inflammatory mechanism, this would mean that the drug is acting directly on disease pathophysiology. I am very excited to see the results of the next study."
REFERENCES
1. Eisai submits supplemental biologics licence application to FDA for traditional approval of Leqembi (lecanemab-irmb) for the treatment of Alzheimer’s disease. News release. January 6, 2023. Accessed February 2, 2023. https://www.prnewswire.com/news-releases/eisai-submits-supplemental-biologics-license-application-to-fda-for-traditional-approval-of-leqembi-lecanemab-irmb-for-the-treatment-of-alzheimers-disease-301715905.html
2. Rubio-Beltrán E, Correnti E, Deen M, et al. PACAP38 and PAC1 receptor blockade: a new target for headache? J Headache Pain. 2018;19(1):64. doi:10.1186/s10194-018-0893-8
3. Kuhlmann T, Moccia M, Coetzee T, et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. Published online November 18, 2022. doi:10.1016/S1474-4422(22)00289-7.
4. Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed critieria. Lancet Neurol. Published online January 24, 2023. doi:10.1016/S1474-4422(22)00431-8.
5. Equilibre Biopharmaceuticals announces positive topline results from phase 2 clinical trial of EQU-001 (NCT05063877) for safety, tolerability, and preliminary efficacy as adjunctive therapy for focal seizures in adults with epilepsy. News release. Equilibre Biopharmaceuticals. January 30, 2023. Accessed February 2, 2023. https://www.biospace.com/article/releases/equilibre-biopharmaceuticals-announces-positive-topline-results-from-phase-2-clinical-trial-of-equ-001-nct05063877-for-safety-tolerability-and-preliminary-efficacy-as-adjunctive-therapy-for-focal-seizures-in-adults-with-epilepsy/
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.